Contact Us
United States - English
China - 简体中文China - 繁體中文Germany – DeutschJapan - 日本語Switzerland - FrançaisUnited States - English

WuXi AppTec News & Press Releases - Latest Pharmaceutical Industry Updates

Access the latest corporate news and announcements for WuXi AppTec, including business milestones, partner collaborations, quality and regulatory updates, and financial results.
Filter By
All Years

2019/03/27

WuXi STA’s New Drug Product Manufacturing Facility Passes First European MPA GMP Inspection

SHANGHAI, March 27, 2019 – STA Pharmaceutical Co., Ltd., (WuXi STA) – a subsidiary of WuXi AppTec – announces that its new drug product manufacturing facility in Shanghai Pilot Free Trade Zone has passed its first GMP inspection by the European Medical Products Agency (MPA). The new facility was opened at the end of 2018, and the successful inspection demonstrates the outstanding quality control system and rapid development of WuXi STA’s drug product services.

Read more

2019/03/22

WuXi AppTec Reports Strong 2018 Annual Results

(SHANGHAI, March 22, 2019) — WuXi AppTec Co., Ltd. (stock code: 603259.SH / 02359.HK), a leading global pharmaceutical and medical device open-access capability and technology platform company with global operations, announces its audited annual results for the year ended December 31, 2018 today.

Read more

2019/03/11

WuXi AppTec Testing Facilities Complete Three Regulatory Inspections from US FDA, OECD, and CNAS with Excellent Results

Shanghai, March 11, 2019 – Three of WuXi AppTec Laboratory Testing Division’s facilities, Drug Safety Testing, Bioanalytical Services and Medical Device Testing, recently completed regulatory inspections from the US FDA (Food and Drug Administration), OECD (Organization for Economic Co-operation and Development), and CNAS (China National Accreditation Service for Conformity Assessment), all with excellent results.

Read more

2019/02/19

WuXi STA and BioLingus sign exclusive technology and marketing collaboration for sublingual delivery

SHANGHAI and SAN DIEGO, February 19, 2019: STA Pharmaceutical Co., Ltd., (WuXi STA), a subsidiary of WuXi AppTec – and BioLingus, a Swiss biotech company, announce they have formed an exclusive technology and marketing collaboration for sublingual delivery.

Read more

2018/12/13

WuXi AppTec Lists H Shares on the Hong Kong Stock Exchange

HONG KONG and SHANGHAI, December 13, 2018-- WuXi AppTec Co., Ltd. (“WuXi AppTec” or “the Company”; Stock code: 603259.SH/2359.HK) today announced the listing of approximately 116 million H-shares on the Main Board of the Hong Kong Stock Exchange. Based on the offer price of HK$68 per share, the net proceeds to be received by the Company are about HK$7,553 million (assuming the Over-allotment Option is not exercised).

Read more